DEBBANE RAYMOND 4

What Happened
Raymond Debbane, a director of Lexicon Pharmaceuticals, reported acquiring 2,000 shares on Feb 25, 2026. The Form 4 shows a purchase (code P) at $1.49 per share for a total reported value of $2,980. This was recorded as an open-market/private purchase (the filing lists the transaction as a purchase rather than a sale).

Key Details

• Transaction date: 2026-02-25; reported on Form 4 filed 2026-02-27.
• Price and size: 2,000 shares at $1.49 per share; total = $2,980.
• Transaction code: P (Purchase).
• Shares owned after transaction: Not disclosed in the information provided in this summary/filing.
• Footnotes or special plans: None indicated (no 10b5-1 plan, tax withholding, or other notes disclosed).
• Timeliness: Filing appears timely (reported two days after the transaction), no late-filing flag shown.

Context
Insider purchases can be interpreted as a positive signal since insiders are buying company stock, but they do not guarantee future performance. This is a relatively small open-market purchase by a director; retail investors should consider it alongside other insider activity and company fundamentals.